However, data regarding grade, site of the tumor in the rectum, pathologic subtype, pretreatment CEA, PNI, LVI and response to neoadjuvant treatment, in addition to RAS-BRAF status, microsatellite instability and EGFR mutations are not part of staging stratifications in spite of being clinically relevant to treatment outcomes, and different treatment guidelines relay dependently on their statuses. The gene discussed is EGFR; the disease is neoplasm.